J Biomed Nanotechnol. 2020 Apr 1;16(4):467-480. doi: 10.1166/jbn.2020.2905.
We developed a vaccine formulation containing ApoB derived P210 peptides as autoantigens, retinoic acid (RA) as an immune enhancer, both of which were delivered using PLGA nanoparticles. The formula was used to induce an immune response in 12-week-old male mice with pre-existing atherosclerotic lesions. The nanotechnology platform PRINT was used to fabricate PLGA nanoparticles that encapsulated RA inside and adsorbed the P210 onto the particle surface. In this study, we demonstrated that immunization of mice with the formulation was able to considerably attenuate atherosclerotic lesions, accompanied by increased P210 specific IgM and another oxidized lipid derived autoantigen, M2AA, specific IgG autoantibodies, and decreased the inflammatory response, as compared to the P210 group with Freund's adjuvant. Our formulation represents an exciting technology to enhance the efficacy of the P210 vaccine.
我们开发了一种疫苗制剂，其中包含载脂蛋白 B 衍生的 P210 肽作为自身抗原，维甲酸 (RA) 作为免疫增强剂，两者均使用 PLGA 纳米粒子递送。该配方用于在具有预先存在的动脉粥样硬化病变的 12 周龄雄性小鼠中诱导免疫反应。纳米技术平台 PRINT 用于制造 PLGA 纳米粒子，该纳米粒子将 RA 包裹在内部，并将 P210 吸附到颗粒表面。在这项研究中，我们证明了用该配方免疫小鼠能够显著减轻动脉粥样硬化病变，同时增加 P210 特异性 IgM 和另一种氧化脂质衍生的自身抗原 M2AA 特异性 IgG 自身抗体，并降低炎症反应，与用弗氏佐剂的 P210 组相比。我们的制剂代表了一种增强 P210 疫苗疗效的令人兴奋的技术。
